These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22203585)

  • 1. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.
    Blais J; Lewis SR; Krause KM; Benton BM
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1584-7. PubMed ID: 22203585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
    Hegde SS; Okusanya OO; Skinner R; Shaw JP; Obedencio G; Ambrose PG; Blais J; Bhavnani SM
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1578-83. PubMed ID: 22155835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
    Leuthner KD; Vidaillac C; Cheung CM; Rybak MJ
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3799-803. PubMed ID: 20585126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
    Tyrrell KL; Citron DM; Warren YA; Goldstein EJ
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2194-7. PubMed ID: 22290981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
    Huang V; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.
    Long DD; Aggen JB; Chinn J; Choi SK; Christensen BG; Fatheree PR; Green D; Hegde SS; Judice JK; Kaniga K; Krause KM; Leadbetter M; Linsell MS; Marquess DG; Moran EJ; Nodwell MB; Pace JL; Trapp SG; Turner SD
    J Antibiot (Tokyo); 2008 Oct; 61(10):603-14. PubMed ID: 19168974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
    Ozmen Capin BB; Tekeli A; Karahan ZC
    Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
    Stryjewski ME; Potgieter PD; Li YP; Barriere SL; Churukian A; Kingsley J; Corey GR;
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5476-83. PubMed ID: 22869571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
    Vidaillac C; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.
    Rolston KVI; Jamal M; Nesher L; Raad I; Rice SA; Rybak MJ; Prince RA
    J Glob Antimicrob Resist; 2019 Jun; 17():16-18. PubMed ID: 30844496
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
    Abbott IJ; Jenney AW; Jeremiah CJ; Mirčeta M; Kandiah JP; Holt DC; Tong SY; Spelman DW
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7837-41. PubMed ID: 26392488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.
    Gould IM
    Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Mohammadi-Berenjestanaki H; Khori V; Shirzad-Aski H; Ghaemi EA
    Microb Drug Resist; 2020 Mar; 26(3):218-226. PubMed ID: 31424323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
    Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci.
    Mohammad H; Mayhoub AS; Cushman M; Seleem MN
    J Antibiot (Tokyo); 2015 Apr; 68(4):259-66. PubMed ID: 25315757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.